gefitinib has been researched along with n-nitrosomorpholine in 1 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (n-nitrosomorpholine) | Trials (n-nitrosomorpholine) | Recent Studies (post-2010) (n-nitrosomorpholine) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 302 | 1 | 27 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Böhning, E; Calvisi, DF; Cigliano, A; Dombrowski, F; Evert, M; Günther, J; Merz, J; Peters, K; Pilo, MG; Ribback, S; Sailer, V; Steinmüller, F; Utpatel, K | 1 |
1 other study(ies) available for gefitinib and n-nitrosomorpholine
Article | Year |
---|---|
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Islets of Langerhans Transplantation; Liver Neoplasms, Experimental; Male; Nitrosamines; Protein Kinase Inhibitors; Quinazolines; ras Proteins; Rats; Rats, Inbred Lew; Sodium-Glucose Transporter 1; Thyroid Epithelial Cells; TOR Serine-Threonine Kinases; Transforming Growth Factor alpha | 2016 |